Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/reel/DHD28nmuKit/So say neurologists at Harvard’s Brigham and Women’s Hospital.  In a mouse model, they show that a nasal spray containing an anti-CD3 monoclonal antibody significantly reduces brain inflammation and speeds recovery after a traumatic brain injury (TBI). This antibody, sprayed into the nasal cavities, activates regulatory T cells, Tregs, that then travel to the brain and release IL-10 that in turn reduces microglial-medial inflammation there.This anti-CD3 nasal spray must still prove its effectiveness in humans.  If so,  it will become a treatment for the TBI that follows concussions, motor vehicle accidents, and other sports-related head trauma.https://www.nature.com/articles/s41593-025-01877-7#traumaticbraininjury #tbi #sports #cd3 #treg #il10 #mva #nasalspray